Home › Funds › Fairmount Funds Management LLC › JBIO
Fairmount Funds Management LLC position in JBIO
JADE BIOSCIENCES INC · Health Care
Fairmount Funds Management LLC reported holding 4,553,494 shares of JBIO (JADE BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$64.0M, representing 4.01% of its reported portfolio and ranking #8 among its reported holdings. Fairmount Funds Management LLC has disclosed JBIO holdings in 6 of the last 6 reported quarters, going back to Q2 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Fairmount Funds Management LLC's JBIO position evolved
Fairmount Funds Management LLC first disclosed a stake in JBIO in Q2 2025 at 3,220,368 shares (US$32.2M). The position peaked in Q2 2026 at 4,553,494 shares, worth US$101.2M. Across 6 filings, Fairmount Funds Management LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 4,553,494 shares valued at US$64.0M. Notable position changes include a 41% increase in Q4 2025 (shares fell 9% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 3.22M | $32.17M | New |
| Q3 2025 | 3.22M | $27.79M | Hold |
| Q4 2025 | 4.55M | $70.26M | Add |
| Q1 2026 | 4.55M | $63.98M | Hold |
| Q2 2026 | 4.55M | $101.18M | Hold |
| Q3 2026 | 4.55M | $63.98M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About JBIO and 13F data
JBIO (JADE BIOSCIENCES INC) is a Health Care company. 81 other funds we track also report a position in JBIO — the largest reported positions include Paradigm Biocapital Advisors LP (US$85.0M), Bellevue Group AG (US$60.3M), Venrock Adviser, LLC (US$45.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding JBIO
- Paradigm Biocapital Advisors LP 6.05M sh · $85.05M · Q3 2026
- Bellevue Group AG 4.29M sh · $60.33M · Q3 2026
- Venrock Adviser, LLC 3.22M sh · $45.25M · Q3 2026
- Avidity Partners Management LP 2.00M sh · $28.10M · Q3 2026
- RA CAPITAL MANAGEMENT, L.P. 1.84M sh · $25.79M · Q3 2026
- Remedium Capital Partners, LLC 1.81M sh · $25.40M · Q3 2026
- BAKER BROS. ADVISORS LP 1.23M sh · $17.29M · Q3 2026
- Soleus Capital Management, L.P. 1.17M sh · $16.45M · Q3 2026
- Versant Venture Management, LLC 991.78K sh · $13.93M · Q3 2026
- ACORN CAPITAL ADVISORS, LLC 986.76K sh · $13.86M · Q3 2026
- Foresite Capital Management VI LLC 886.67K sh · $12.46M · Q3 2026
- Affinity Asset Advisors, LLC 760.35K sh · $10.68M · Q3 2026
More on Fairmount Funds Management LLC
FAQ
How long has Fairmount Funds Management LLC held JBIO?
Fairmount Funds Management LLC has disclosed JBIO holdings in 6 of the last 6 reported quarters, going back to Q2 2025.
What is Fairmount Funds Management LLC's current position in JBIO?
As of Q3 2026, Fairmount Funds Management LLC holds 4.55M shares of JBIO (JADE BIOSCIENCES INC), valued at $63.98M, representing 4.01% of its reported portfolio and ranking #8.
Has Fairmount Funds Management LLC been buying or selling JBIO?
In the latest 13F filing (Q3 2026), Fairmount Funds Management LLC held unchanged its position in JBIO. The position peaked in Q2 2026 at 4.55M shares.
Which other funds hold JBIO?
Other major institutional holders of JBIO include Paradigm Biocapital Advisors LP, Bellevue Group AG, Venrock Adviser, LLC, among 81 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.